Skip to main content
رجوع
BIO logo

Bio-Rad Laboratories, Inc.

جودة البيانات: 100%
BIO
NYSE Healthcare Medical - Devices
KWD 272.12
▲ KWD 7.12 (2.69%)
القيمة السوقية: 7.34B
نطاق اليوم
KWD 261.29 KWD 273.79
نطاق 52 أسبوعًا
KWD 211.43 KWD 343.12
حجم التداول
293,252
متوسط 50 يوم / 200 يوم
KWD 287.77 / KWD 286.16
الإغلاق السابق
KWD 265.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 9.7 0.4
P/B 1.0 2.9
ROE % 10.8 3.7
Net Margin % 29.4 3.9
Rev Growth 5Y % -3.0 10.0
D/E 0.2 0.2

السعر المستهدف للمحللين

Hold
KWD 327.500 +20.4%
Low: KWD 320.000 High: KWD 335.000
مكرر الربحية المستقبلي
25.9
ربحية السهم المستقبلية
KWD 10.251
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
2.6 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 14.300
KWD 14.025 – KWD 14.565
 2.9 B 1
FY2028 KWD 12.532
KWD 12.291 – KWD 12.765
 2.8 B 1
FY2027 KWD 11.500
KWD 11.279 – KWD 11.714
 2.7 B 2

النقاط الرئيسية

Revenue declined -3.04% annually over 5 years
ROE of 10.84% — decent returns on equity
Net margin of 29.42% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 374.60M in free cash flow
P/E of 9.67 — trading at a low valuation

النمو

Revenue Growth (5Y)
-3.04%
Revenue (1Y)0.65%
Earnings (1Y)N/A
FCF Growth (3Y)31.01%

الجودة

Return on Equity
10.84%
ROIC2.26%
Net Margin29.42%
Op. Margin10.47%

الأمان

Debt / Equity
0.21
Current Ratio5.62
Interest Coverage5.52

التقييم

P/E Ratio
9.67
P/B Ratio0.99
EV/EBITDA30.85
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.65% Revenue Growth (3Y) -1.66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -3.04% Earnings Growth (5Y) -34.99%
Profitability
Revenue (TTM) 2.58B Net Income (TTM) 759.90M
ROE 10.84% ROA 7.18%
Gross Margin 52.01% Operating Margin 10.47%
Net Margin 29.42% Free Cash Flow (TTM) 374.60M
ROIC 2.26% FCF Growth (3Y) 31.01%
Safety
Debt / Equity 0.21 Current Ratio 5.62
Interest Coverage 5.52 Dividend Yield 0.00%
Valuation
P/E Ratio 9.67 P/B Ratio 0.99
P/S Ratio 2.84 PEG Ratio -0.08
EV/EBITDA 30.85 Dividend Yield 0.00%
Market Cap 7.34B Enterprise Value 8.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.58B 2.57B 2.67B 2.80B 2.92B
Net Income 759.90M -1.84B -637.32M -3.63B 4.25B
EPS (Diluted) 27.87 -65.36 -21.82 -121.79 140.83
Gross Profit 1.34B 1.38B 1.43B 1.57B 1.64B
Operating Income 270.50M 269.00M 337.80M 482.62M 500.34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 10.58B 9.36B 12.30B 13.50B 17.80B
Total Liabilities 3.12B 2.79B 3.56B 3.89B 4.11B
Shareholders' Equity 7.45B 6.57B 8.74B 9.62B 13.69B
Total Debt 1.53B 1.37B 1.41B 1.39B 223.38M
Cash & Equivalents 531.80M 488.10M 403.80M 434.22M 470.78M
Current Assets 2.91B 3.03B 3.05B 3.16B 1.99B
Current Liabilities 517.00M 467.80M 522.80M 568.71M 680.94M

درجات الاستراتيجيات

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#605 of 820
33
Value Defensive Investing (Benjamin Graham)
#258 of 708
35

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026